3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
8
Completed
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Myelodysplastic Syndromes
26
Hematologic Neoplasms
20
Lymphoma, Non-Hodgkin
19
Multiple Myeloma
18
Lymphoma
18
Recurrence
15
Lymphoma, B-Cell
14
Lymphoma, Large B-Cell, Diffuse
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Burkitt Lymphoma
12
Breast Neoplasms
11
Pancreatic Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Follicular
10
Neoplasm Metastasis
9
Melanoma
9
Leukemia, Myelomonocytic, Chronic
9
Myeloproliferative Disorders
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Leukemia, Biphenotypic, Acute
7
Leukemia
7
Hodgkin Disease
7
Glioblastoma
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Osteosarcoma
6
Interventions
pembrolizumab
6
cabozantinib
6
Nivolumab
5
Ipilimumab
5
Axitinib
5
Radiosurgery
3
Blood Specimen Collection
3
zimberelimab
2
lenvatinib
2
Ultrasonography
2
Radiotherapy
2
Biopsy
2
tislelizumab
1
polyethylene glycol 3350
1
pazopanib
1
palbociclib
1
orellanine
1
olaparib
1
gallium Ga 68 dotatate
1
fludarabine
1
cyclopropapyrroloindole
1
brodalumab
1
belzutifan
1
atezolizumab
1
anlotinib
1
adagrasib
1
Watchful Waiting
1
Vincristine
1
Therapeutics
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Kidney Neoplasms
×
fludarabine
×
Clear all
NCT07551349
2026-04-24
DUAL-NK RCC
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled